^
Association details:
| Biomarker: | TNFRSF8 positive |
|---|---|
| Cancer: | Lymphoma |
| Drug: | Adcetris (brentuximab vedotin) (Microtubule inhibitor, CD30-targeted antibody-drug conjugate) + SGN-CD30C (Topoisomerase I inhibitor, CD30-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
SGN-CD30C, an Investigational CD30-Directed Camptothecin Antibody-Drug Conjugate (ADC), Shows Strong Anti Tumor Activity and Superior Tolerability in Preclinical Studies
Excerpt:
Moreover, SGN-CD30C exhibits many of the desirable attributes associated with BV, notably, bystander activity and CD30+ T regulatory cell (Treg) depletion...In summary, our data show SGN-CD30C is a compelling therapeutic candidate for CD30-positive malignancies. The distinct mechanism of action, strong anti-tumor activity, and enhanced tolerability provide a strong rationale to clinically investigate SGN-CD30C across the CD30-expressing lymphoma landscape.
DOI:
10.1182/blood-2020-136577
Source:
Title:
Abstract 2889: SGN-CD30C, a new CD30-directed camptothecin antibody-drug conjugate (ADC), shows strong anti-tumor activity and superior tolerability in preclinical studies
Excerpt:
The results show the combination of SGN-CD30C + BV generated a higher number of durable CRs compared to the equivalent monotherapy doses, thereby confirming strong anti-tumor activity by using a lower dose of each ADC in combination...In summary, our data show SGN-CD30C is a compelling therapeutic candidate for CD30-positive malignancies. The strong anti-tumor activity and superior tolerability suggest SGN-CD30C has a favorable therapeutic window.
DOI:
10.1158/1538-7445.AM2020-2889
